Insulin Therapy in Small Animals, Part 2: Cats

Area of Science:

• Veterinary Medicine
• Endocrinology
• Pharmacology

Background:

• Feline diabetes mellitus is a common endocrine disorder requiring lifelong management.
• Insulin therapy is the cornerstone of treatment, but optimal formulation selection remains debated.
• Understanding insulin pharmacokinetics is essential for effective glycemic control in cats.

Purpose of the Study:

• To evaluate the suitability of different insulin formulations for basal insulin therapy in cats.
• To determine which insulin formulation best meets the constant basal insulin requirements of diabetic cats.
• To provide guidance on selecting appropriate insulin for feline diabetes management.

Main Methods:

• Review of pharmacokinetic and pharmacodynamic data of various insulin formulations in cats.
• Analysis of insulin action profiles in relation to feline physiological needs.
• Comparison of insulin glargine U100 and U300, and other common insulin types.

Main Results:

• No single insulin formulation is universally best for feline diabetes; individualized selection is key.
• Basal insulin therapy can normalize blood glucose in cats with residual beta-cell function.
• Insulin glargine U300 exhibits a pharmacokinetic profile closest to ideal basal insulin requirements in cats, with relatively consistent action throughout the day.

Conclusions:

• Insulin choice for feline diabetes should be based on the individual cat's clinical status.
• Insulin glargine U300 demonstrates the most consistent, long-acting profile suitable for basal insulin therapy in cats.
• Further research may explore other formulations, but insulin glargine U300 currently best approximates ideal basal insulin characteristics for feline use.